NASDAQ: SYRE
Spyre Therapeutics Inc Stock Ownership - Who owns Spyre Therapeutics?

Insider buying vs selling

Have Spyre Therapeutics Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Cameron TurtleChief Executive Officer2026-02-02957$31.82
$30.45kSell
Cameron TurtleChief Executive Officer2026-02-0214,043$32.87
$461.59kSell
Cameron TurtleChief Executive Officer2026-01-0212,709$30.47
$387.24kSell
Cameron TurtleChief Executive Officer2026-01-022,191$31.79
$69.65kSell
Cameron TurtleChief Executive Officer2026-01-02100$32.39
$3.24kSell
Cameron TurtleChief Executive Officer2025-12-0110,995$28.73
$315.89kSell
Cameron TurtleChief Executive Officer2025-12-014,005$29.83
$119.47kSell
Cameron TurtleChief Executive Officer2025-11-0316,845$23.66
$398.55kSell
Cameron TurtleChief Executive Officer2025-11-0328,155$23.13
$651.23kSell
Scott L. BurrowsChief Financial Officer2025-09-0218,428$16.26
$299.64kSell

1 of 1

SYRE insiders have sold more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when SYRE insiders and whales buy or sell their stock.

SYRE Shareholders

What type of owners hold Spyre Therapeutics Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Fairmount Funds Management LLC18.43%14,301,760$485.12MInsider
Fmr LLC11.68%9,060,144$307.32MInstitution
Fairmount Funds Management LLC5.18%4,018,101$136.29MInstitution
Blackrock Inc5.13%3,982,744$135.09MInstitution
Rtw Investments LP4.67%3,621,996$122.86MInstitution
Tang Capital Management LLC4.12%3,200,000$108.54MInstitution
Baker Bros Advisors LP3.99%3,094,590$104.97MInsider
Vanguard Group Inc3.93%3,050,730$103.48MInstitution
Orbimed Advisors LLC3.65%2,829,748$95.99MInsider
Vr Adviser LLC3.46%2,685,448$91.09MInstitution

1 of 3

SYRE vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
SYRE71.36%28.64%Net SellingNet Selling
IRON57.71%42.29%Net SellingNet Selling
VERA66.78%33.22%Net BuyingNet Buying
TARS73.40%26.60%Net SellingNet Selling
BEAM86.38%13.62%Net SellingNet Selling

Spyre Therapeutics Stock Ownership FAQ

Who owns Spyre Therapeutics?

Spyre Therapeutics (NASDAQ: SYRE) is owned by 82.87% institutional shareholders, 33.26% Spyre Therapeutics insiders, and 0.00% retail investors. Fairmount Funds Management LLC is the largest individual Spyre Therapeutics shareholder, owning 14.30M shares representing 18.43% of the company. Fairmount Funds Management LLC's Spyre Therapeutics shares are currently valued at $498.27M.

If you're new to stock investing, here's how to buy Spyre Therapeutics stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.